Close Menu

Memorial Sloan-Kettering

Starting with a head and neck cancer patient who showed an impressive response to pembrolizumab, researchers profiled gene fusion neoantigens in several tumor types.

The center received a response to its initial submission to the NY State Department of Health in February and will re-submit by the end of this month.

 

Presenters at the 2019 annual meeting's opening plenary spoke about merging technologies in order to individualize care for their patients.

In the hunt for an antigen in solid tumors that CAR T cells can target, researchers demonstrate the safety and efficacy profile of two such agents in early studies.

Researchers reported finding oncohistone mutations within nearly 4 percent of tumors and said they could alter the structure and function of chromatin.

MSK's PathoMAN achieved 94 percent and 81 percent concordance with results from three commercial labs for pathogenic and benign variants, respectively.

The firm's lab subsidiary Phenogen will provide genotyping to study the impact on women's decisions to undergo prophylactic surgery.

In Nature this week: study of gene drive feasibility in lab mice, circulating tumor DNA from cerebrospinal fluid to track glioma progression, and more.

The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Pages

The US Department of Justice has proposed a rule change to enable DNA to be collected from migrants, the Associated Press reports.

Bernard Fisher, a surgeon who changed how breast cancer is treated, has died at 101, the New York Times reports.

Washington Post columnist writes that she is skeptical about DNA-based diets.

In PNAS this week: recurrent inactivation of DEPDC5 in gastrointestinal stromal tumors, taxonomic reliability of GenBank sequences, and more.